Posted in:Legal The Patent Dance Goes on for Genentech and Amgen Over Bevacizumab (Avastin®) By C. Nichole Gifford and Daniel McCallum April 20, 2017 Comments are off Genentech filed suit against Amgen this past February when a dispute arose between the parties during the first step of the “patent... Read more Tagged with: Amgen, Avastin®, bevacizumab, BPCIA, District Court, Genentech, Genentech v. Amgen, Legal, Litigation, Patent Dance http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:Legal Complaint in Genentech v. Amgen Dismissed Without Prejudice By Daniel McCallum and C. Nichole Gifford March 2, 2017 Comments are off Genentech’s lawsuit against Amgen has come to a quick (although perhaps temporary) end, with the Court dismissing Genentech’s complaint... Read more Tagged with: Amgen, Avastin®, bevacizumab, BPCIA, District Court, Genentech, Genentech v. Amgen, Legal, Litigation, Patent Dance http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus
Posted in:Legal Genentech Sues Amgen Over BPCIA Disclosures for Avastin® (bevacizumab) By C. Nichole Gifford February 20, 2017 Comments are off On February 15, 2017, Genentech filed litigation accusing Amgen of violating the Biologics Price Competition and Innovation Act... Read more Tagged with: Avastin®, bevacizumab, BPCIA, District Court, Genentech v. Amgen, Legal, Litigation, Patent Dance http://twitter.com/share?text="[TITLE]&url=[PERMALINK]ShareEmail, Linked In, Twitter, Facebook, Google Plus